Introducing BD Simplist™ a line of ready-to-administer prefilled injectables designed with high safety standards in mind: yours1
Ondansetron Injection is a 5-HT3 receptor antagonist indicated for:
Prevention of nausea and/or vomiting postoperatively and with initial and repeat courses of emetogenic cancer chemotherapy.
Important Safety Information (ISI)
Ondansetron Injection is contraindicated in patients known to have hypersensitivity (e.g. anaphylaxis) to this product or any of its components and in the concomitant use of apomorphine.
Hypersensitivity reactions including anaphylaxis and bronchospasm have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. QT prolongation occurs in a dose-dependent manner. Torsades de Pointes have been reported. Avoid Ondansetron in patients with congenital long QT syndrome. Use in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distention.
The most common adverse reactions in adults are headache, diarrhea and fever. In pediatric patients (ages 1 to 24 months), the most common adverse reaction is diarrhea.
Please see full prescribing information for additional Important Safety Information here